Xencor | XNCR - Assets


Xencor reported $868.81M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Arrowhead Research USD 1.39B 4.68M Sep/2025
AstraZeneca USD 114.46B 2.03B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
GlaxoSmithKline GBP 61.34B 2.08B Sep/2025
J&J USD 192.82B 573M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Xencor USD 868.81M 10.61M Sep/2025